The FDA has classified BPC-157 in Category 2 for bulk drug substances, citing possible safety issues in compounding, such as immunogenicity, impurities, and insufficient safety evidence for suggested administration routes
Best delivery method: GHK-Cu via subcutaneous injection or topical
FDA evaluated BPC-157 free base and acetate for ulcerative colitis under the clinical-need question
Experiencing acid reflux once or twice weekly may not warrant significant intervention
Nishimoto, S., Tanaka, H., Okamoto, M., Okada, K., Murase, T., & Yoshikawa, H
Furthermore, dihexa is thought to cross the blood-brain barrier effectively, delivering its benefits directly to the central nervous system, which is a significant advantage in neurological therapies